Literature DB >> 35879767

Feasibility research of enhanced recovery after surgery implemented in esophageal cancer patients who underwent neoadjuvant chemotherapy.

Zhanpeng Tang1, Xirui Zhu1, Yanzhi Li1, Chenghao Qu1, Lin Li1, Shuhai Li1, Lei Qi1, Ming Lu1, Chuanle Cheng1, Hui Tian2.   

Abstract

BACKGROUND: Enhanced recovery after surgery (ERAS) is a perioperative management protocol to accelerate patient recovery. This study aimed to evaluate the feasibility of ERAS protocols implemented in patients who underwent neoadjuvant chemotherapy (NACT) before minimally invasive McKeown esophagectomy.
METHODS: This retrospective study compared the short-term clinical outcomes in esophagectomy patients from June 2018 to June 2021. Subjects were divided into two categories: those who underwent NACT (NACT group) and the non-NACT group.
RESULTS: There was no significant difference in total postoperative complication morbidity between the NACT and non-NACT groups (21.2% vs. 20.7%, P=0.936). In addition, the hospital length of stay post-surgery (7.90 vs. 7.71 days, P=0.424) was not significantly longer when compared to the non-NACT group. The time to chest tube removal (5.37 vs. 5.13 days, P=0.238) and first bowel movement (2.92 vs. 3.01 days, P=0.560) was also similar between the two groups.
CONCLUSIONS: There was no significant difference in postoperative complications rate, postoperative hospital length of stay, and readmission rate between the two group. This study proved that ERAS protocols seemed to be safe and feasible for patients who received NACT before esophagectomy.
© 2022. The Author(s).

Entities:  

Keywords:  Enhanced recovery after surgery (ERAS); Esophageal squamous cell carcinoma (ESCC); Esophagectomy; Neoadjuvant chemotherapy

Mesh:

Year:  2022        PMID: 35879767      PMCID: PMC9310402          DOI: 10.1186/s12957-022-02701-3

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   3.253


  20 in total

Review 1.  Multimodal approach to control postoperative pathophysiology and rehabilitation.

Authors:  H Kehlet
Journal:  Br J Anaesth       Date:  1997-05       Impact factor: 9.166

2.  Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Tomoki Makino; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  J Surg Oncol       Date:  2015-07-14       Impact factor: 3.454

Review 3.  Diagnosis, assessment, and management of surgical complications following esophagectomy.

Authors:  Peter P Grimminger; Lucas Goense; Ines Gockel; Damien Bergeat; Nicolas Bertheuil; Servarayan M Chandramohan; Ke-Neng Chen; Seung-Hon Chon; Collet Denis; Khean-Lee Goh; Caroline Gronnier; Jun-Feng Liu; Bernard Meunier; Phillippe Nafteux; Enrique D Pirchi; Marc Schiesser; René Thieme; Aaron Wu; Peter C Wu; Navtej Buttar; Andrew C Chang
Journal:  Ann N Y Acad Sci       Date:  2018-07-08       Impact factor: 5.691

4.  Comparison of "Nil by Mouth" Versus Early Oral Intake in Three Different Diet Regimens Following Esophagectomy.

Authors:  Kristine Elisabeth Eberhard; Michael Patrick Achiam; Hans Christian Rolff; Mohamed Belmouhand; Lars Bo Svendsen; Morten Thorsteinsson
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

Review 5.  Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis.

Authors:  Lei Jiang; Ke-hu Yang; Quan-lin Guan; Yan Chen; Peng Zhao; Jin-hui Tian
Journal:  J Clin Gastroenterol       Date:  2015 May-Jun       Impact factor: 3.062

6.  The benefits of enhanced recovery after surgery for gastric cancer: A large before-and-after propensity score matching study.

Authors:  Oh Jeong; Aelee Jang; Mi Ran Jung; Ji Hoon Kang; Seong Yeob Ryu
Journal:  Clin Nutr       Date:  2020-10-01       Impact factor: 7.324

7.  Early Oral Feeding Following McKeown Minimally Invasive Esophagectomy: An Open-label, Randomized, Controlled, Noninferiority Trial.

Authors:  Hai-Bo Sun; Yin Li; Xian-Ben Liu; Rui-Xiang Zhang; Zong-Fei Wang; Toni Lerut; Chia-Chuan Liu; Alfonso Fiorelli; Yin-Kai Chao; Daniela Molena; Robert J Cerfolio; Soji Ozawa; Andrew C Chang
Journal:  Ann Surg       Date:  2018-03       Impact factor: 12.969

8.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 9.  Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.

Authors:  Yoshihiro Kakeji; Taro Oshikiri; Gosuke Takiguchi; Shingo Kanaji; Takeru Matsuda; Tetsu Nakamura; Satoshi Suzuki
Journal:  Esophagus       Date:  2020-09-22       Impact factor: 4.230

10.  Patients Administered Neoadjuvant Chemotherapy Could be Enrolled into an Enhanced Recovery after Surgery Program for Locally Advanced Gastric Cancer.

Authors:  Jian Zhao; Gang Wang; Zhi-Wei Jiang; Chuan-Wei Jiang; Jiang Liu; Can-Can Xia; Jie-Shou Li
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.